Virtus LifeSci Biotech Clinical Trials ETF
16 hedge funds and large institutions have $5.97M invested in Virtus LifeSci Biotech Clinical Trials ETF in 2022 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 4 reducing their positions, and 1 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more capital invested
Capital invested by funds: $ → $
more funds holding
Funds holding: →
more ownership
Funds ownership: →
50% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 4
Holders
16
Holding in Top 10
–
Calls
–
Puts
–
Top Buyers
| 1 | +$894K | |
| 2 | +$499K | |
| 3 | +$24.1K | |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$15.9K |
Top Sellers
| 1 | -$849K | |
| 2 | -$37.4K | |
| 3 | -$14K | |
| 4 |
Morgan Stanley
New York
|
-$2.36K |
| 5 |
GRP
Global Retirement Partners
San Rafael,
California
|
-$515 |